Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03790332 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)
A Phase 1 study, sponsored by Pharmacyclics.
- Completed
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
NCT03790332 is a Phase 1 study that has completed, run by Pharmacyclics. The registered enrollment target is 59 participants.
The verdict
NCT03790332, a Phase 1 study, has completed, sponsored by Pharmacyclics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
Study Summary
Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD)
Interventions
- DRUG Ibrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2018-11-19 |
| Est. Completion | 2025-10-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03790332
The ClinicalTrials.gov registry entry for NCT03790332 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ibrutinib is the first listed.
NCT03790332 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03790332 about?
NCT03790332 is a clinical study titled "Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)". Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD)
What is the current status of trial NCT03790332?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2018-11-19. Estimated completion is 2025-10-09.
What interventions are being tested in trial NCT03790332?
The interventions under investigation include: Ibrutinib (DRUG).
Who is sponsoring clinical trial NCT03790332?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.